Checkmate Pharmaceuticals Aktie - CMPI

Professionelle Tools für Privatanleger.

Premium

Current Price

10,50

Gebot

10,50

Fragen

10,50

Volumen

0,00 Tagesbereich 0,00

0,00 52-Wochen-Bereich 0,00

Handelsende

10,50

Handelsbeginn

Letzte Trade

Letzter Handelszeitpunkt

Durchschnittliches Volumen (3 Mio.)

Finanzvolumen

VWAP

University of Iowa Holden Comprehensive Cancer Center Presents Preliminary Data from Clinical Trial of Vidutolimod at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

CAMBRIDGE, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI...

Checkmate Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business Update

CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (Nasdaq: CMPI...

Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types

Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types PR...

Checkmate Pharmaceuticals Presents Clinical Trial Biomarker Data with Vidutolimod at the 2022 American Association for Cancer Research (AACR) Annual Meeting

CAMBRIDGE, Mass., April 08, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI...

Checkmate Pharmaceuticals Announces Full Year 2021 Financial Results and Provides Business Update

Alan Bash, experienced biopharmaceutical executive, appointed President and CEO Clinical trials with...

Checkmate Pharmaceuticals to Present at the 2022 American Association for Cancer Research (AACR) Annual Meeting

CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI...

Checkmate Pharmaceuticals Appoints Alan Bash as President and CEO

CAMBRIDGE, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (Nasdaq: CMPI...

Checkmate Pharmaceuticals Welcomes Industry Leader Jon Wigginton, M.D. to its Board of Directors

CAMBRIDGE, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI...

Checkmate Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference

CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

CMPI - Frequently Asked Questions (FAQ)

What is the current Checkmate Pharmaceuticals share price?

The current share price of Checkmate Pharmaceuticals is US$ 10,50

What is the 1 year trading range for Checkmate Pharmaceuticals share price?

Checkmate Pharmaceuticals has traded in the range of US$ 0,00 to US$ 0,00 during the past year

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
IMTEIntergrated Media Technology Ltd	US$ 1,25 (131,52%)	15,05M
XHLDTEN Holdings Inc	US$ 2,22 (58,57%)	9,39M
JFBJFB Construction Holdings	US$ 6,90 (58,26%)	35
MLGOMicroAlgo Inc	US$ 3,41 (35,32%)	10,12M
WINTWindtree Therapeutics Inc	US$ 1,94 (31,08%)	8,64M
ME23andMe Holding Company	US$ 1,03 (-42,46%)	146,19k
UBXUNITY Biotechnology Inc	US$ 1,19 (-34,79%)	302,93k
RNAZTransCode Therapeutics Inc	US$ 0,78 (-30,36%)	2,65M
LGHLLion Group Holding Ltd	US$ 0,074 (-25,70%)	75,97k
NVNINVNI Group Ltd	US$ 0,1811 (-25,41%)	3,02M
DMNDamon Inc	US$ 0,043 (15,28%)	54,32M
IMTEIntergrated Media Technology Ltd	US$ 1,25 (131,52%)	15,05M
TSLLDirexion Daily TSLA Bull 2X Trust ETF	US$ 9,66 (6,86%)	10,86M
MLGOMicroAlgo Inc	US$ 3,41 (35,32%)	10,12M
XHLDTEN Holdings Inc	US$ 2,22 (58,57%)	9,39M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Checkmate Pharmaceuticals Inc (CMPI)

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

CMPI Neueste Nachrichten

University of Iowa Holden Comprehensive Cancer Center Presents Preliminary Data from Clinical Trial of Vidutolimod at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Checkmate Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business Update

Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types

Checkmate Pharmaceuticals Presents Clinical Trial Biomarker Data with Vidutolimod at the 2022 American Association for Cancer Research (AACR) Annual Meeting

Checkmate Pharmaceuticals Announces Full Year 2021 Financial Results and Provides Business Update

Checkmate Pharmaceuticals to Present at the 2022 American Association for Cancer Research (AACR) Annual Meeting

Checkmate Pharmaceuticals Appoints Alan Bash as President and CEO

Checkmate Pharmaceuticals Welcomes Industry Leader Jon Wigginton, M.D. to its Board of Directors

Checkmate Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference

CMPI - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Checkmate Pharmaceuticals Inc (CMPI) Börsenkurse

Checkmate Pharmaceuticals Inc (CMPI)

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

CMPI Neueste Nachrichten

University of Iowa Holden Comprehensive Cancer Center Presents Preliminary Data from Clinical Trial of Vidutolimod at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Checkmate Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business Update

Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types

Checkmate Pharmaceuticals Presents Clinical Trial Biomarker Data with Vidutolimod at the 2022 American Association for Cancer Research (AACR) Annual Meeting

Checkmate Pharmaceuticals Announces Full Year 2021 Financial Results and Provides Business Update

Checkmate Pharmaceuticals to Present at the 2022 American Association for Cancer Research (AACR) Annual Meeting

Checkmate Pharmaceuticals Appoints Alan Bash as President and CEO

Checkmate Pharmaceuticals Welcomes Industry Leader Jon Wigginton, M.D. to its Board of Directors

Checkmate Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference

CMPI - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS